Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation.

Patient eligibility

Treatment with aflibercept, ranibizumab and verteporfin can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 for patients with subfoveal choroidal neovascularisation.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing aflibercept, ranibizumab and verteporfin.

Applications

Patients must be treated by an ophthalmologist or in consultation with an ophthalmologist to be eligible for PBS subsidised treatment with these medications.

Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised aflibercept, ranibizumab and verteporfin for the treatment of patients with subfoveal choroidal neovascularisation in writing and:

All applications must include the completed :

If urgent, you can fax the first authority application to us on 1300 093 177 Monday to Friday during operating hours from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.

Continuing treatment

To make continuing applications for treatment with aflibercept and ranibizumab call the PBS Complex Drugs Programs enquiry line.

Continuing treatment with verteporfin is Authority Required (Streamlined) and doesn’t require prior authority approval from us.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 5 July 2018